Coleneuramide

Drug Profile

Coleneuramide

Alternative Names: MCC-257

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Mitsubishi Tanabe Pharma Corporation
  • Class Analgesics
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic neuropathies

Most Recent Events

  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku Co. Ltd to form Mitsubishi Tanabe Pharma Corporation
  • 11 May 2006 Phase-II clinical trials in Diabetic neuropathies in USA (PO)
  • 06 Aug 2003 No development reported - Preclinical for Diabetic neuropathies in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top